题名

單株抗體治療新冠肺炎經驗

并列篇名

Experience of Using Monoclonal Antibodies for COVID-19

DOI

10.6320/FJM.202111_25(6).0007

作者

楊家瑞(Chia-Jui Yang)；蔡茂松(Mao-Song Tsai)；劉佳穎(Chia-Ying Liu)；蔡欣諺(Hsin-Yen Tsai)；陳泓恩(Hong-An Chen)；廖俊星(Chun-Hsing Liao)

关键词

中和性單株抗體 ； 新冠肺炎 ； 被動免疫 ； 新型冠狀病毒 ； neutralizing monoclonal antibodies ； COVID-19 ； passive immunity ； SARS-COV-2

期刊名称

台灣醫學

卷期/出版年月

25卷6期（2021 / 11 / 25）

页次

763 - 770

内容语文

繁體中文
中文摘要

自從2021年5月中旬，北台灣爆發新冠肺炎（COVID-19）以來，快速增加的嚴重，或是重症病患衝擊了醫療照護體系，以及重症加護的能量。老年人和具有慢性共病疾患，例如高血壓、糖尿病、或是慢性腎病等，都是發展為重症或是死亡的高危險群。除了使用類固醇或是瑞德西韋治療嚴重的COVID-19病人，也有越來越多的證據支持，使用中和性單株抗體，能夠減少輕度或是中度COVID-19患者的住院或是死亡率。為了在台灣這一波社區流行中，減少COVID-19輕度和中度患者的病情惡化或是死亡，自2021年6月中旬起，引進單株抗體治療輕症，但是高風險的患者。至2021年7月底為止，我們使用了casirivimab／imdevimab以及bamlanivimab／etesevimab治療了26位，至少具有一項風險因子的患者。沒有任何一位接受單株抗體治療的患者，有出現病情惡化或是死亡。
英文摘要

As a surge of COVID-19 cases in northern Taiwan since mid-May 2021, rapidly escalated severe or critical ill patients impacted our health care system and intensive care reserve capacity. Elderly people and those who had comorbidities such as hypertension, diabetes or chronic kidney disease were at high risk for development of critical disease or death. Except for using steroids and remdesivir as treatment options for COVID-19 patients with severe disease, more and more evidence supported the use of neutralizing monoclonal antibodies to decrease hospitalization rate and mortality of COVID-19 for patients with mild to moderate disease. To avoid disease progression among COVID-19 patients who have mild to moderate disease, monoclonal antibodies for COVID-19 had been used to at risk patients since mid-June 2021. Before the end of July 2021, we used casirivimab/imdevimab and bamlanivimab/etesevimab for 26 COVID-19 patients who had at least one risk factor of disease progression in Far Eastern Memorial Hospital. No disease progression or death had been observed after treatment with monoclonal antibodies.
主题分类 醫藥衛生 > 醫藥衛生綜合
参考文献
  1. Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021;19:141-54.
    連結：
  2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
    連結：
  3. Ioannidis JP. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ 2021;99:19-33F.
    連結：
  4. Grasselli G, Greco M, Zanella A, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in lombardy, Italy. JAMA Intern Med 2020;180:1345-55.
    連結：
  5. Renn A, Fu Y, Hu X, et al. Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2. Trends Pharmacol Sci 2020;41:815-29.
    連結：
  6. Bolle A, Davies MA, Hussey H, et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis 2020 Aug 29;ciaa1198.
    連結：
  7. Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 2020;369:1014-8.
    連結：
  8. Weinreich, DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 2021;384:238-51.
    連結：
  9. ACTIV-3/TICO Study Group. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med 2021;384:905-14.
    連結：
  10. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY- CoV555 in outpatients with Covid-19. N Engl J Med 2021;384:229-37.
    連結：
  11. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med 2021; NEJMoa2102685.
    連結：
  12. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 2021;596:276-80.
    連結：
  13. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
    連結：
  14. Webb BJ, Buckel W, Vento T, et al. Real-world effectiveness and tolerability of monoclonal antibody therapy for ambulatory patients with early COVID-19. Open Forum Infect Dis 2021;8:ofab331.
    連結：
  15. Farcy DA, Dalley MT, Miro G, et al. A comparison of SARS-COV-2 neutralizing antibody therapies in high-risk patients with mild to moderate COVID-19 disease at a single academic hospital. J Emerg Med 2021;S0736-4679(21)00564-3.
    連結：
  16. Ganesh R, Philpot LM, Bierle DM, et al. Real-world clinical outcomes of Bamlanivimab and Casirivimab-Imdevimab among high-risk patients with mild to moderate coronavirus disease 2019. J Infect Dis 2021 Jul 19;jiab377.
    連結：
  17. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/ Accessed June 11, 2021.
  18. Kumar S, Chandele A, Sharma A. Current status of therapeutic monoclonal Abs against SARS-CoV-2. PLoS Pathog 2021;17:e1009885.
  19. Regeneron Pharmaceuticals Inc. Fact sheet for health care providers: emergency use authorization (EUA) of casirivimab and imdevimab. https:// www.regeneron.com/sites/ default/files/treatment- covid19-eua-fact-sheet-for-hcp.pdf/ Accessed June 11, 2021.
  20. RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, 2021. medRxiv doi: 10.1101/2021.06.15.21258542
  21. REGN-COV2 phase 3: https://www.roche.com/ media/releases/med-cor-2021-03-23.htm./ Accessed June 11, 2021.
  22. US Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab, 2020. FDA https://www.fda.gov/ media/ 143603/ download/ Accessed June 11, 2021.
print cancel